1. Pink Sheet
  2. >>Product Reviews

April CHMP Meeting: Disappointment In Advance For AB Science, Gilead Hopeful On Biktarvy

 
• By Maureen Kenny

The European Medicines Agency’s CHMP is deciding the fate of several new drugs at its April meeting, which is taking place this week.  

3d different tablets and pills on a white background with question marks
Which new drugs will the EMA recommend for approval this week? • Source: Shutterstock

Just four products are listed as being up for an opinion on whether they should be approved for sale across the EU at the latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), under way this week in London.

The CHMP has already adopted a negative opinion on one of the four marketing authorization applications in question – AB Science’s would-be amyotrophic lateral sclerosis (ALS) treatment, Alsitek (masitinib) – so that leaves three: Gilead Sciences’s fixed-dose combination therapy for HIV, bictegravir/emtricitabine/tenofovir alafenamide (approved in the US in February this year as Biktarvy (Also see "

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

Keep Talking: US FDA’s Beleaguered Biologics Center Remains Vital To Regenerative Medicine

 
• By Bridget Silverman

Advisory committee for Capricor’s deriamocel planned, regenerative medicine advanced therapy designations proliferate for osteoarthritis, and the ranks of dual RMAT/breakthrough therapy designation holders grow.

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

US FDA Advisory Committee Misperceptions Abound … At HHS

 
• By Michael McCaughan

HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.

US FDA Layoffs Hit Conflict-Of-Interest Screening For ODAC Meeting

 
• By Sue Sutter and Derrick Gingery

Screening for conflicts and finding the right expertise for a two-day Oncologic Drugs Advisory Committee meeting on four products has been complicated by the Trump Administration’s initial communications freeze and subsequent layoffs in CDER.

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.